Literature DB >> 26825088

Long-Term Cognitive and Functional Outcomes in Children with Mucopolysaccharidosis (MPS)-IH (Hurler Syndrome) Treated with Hematopoietic Cell Transplantation.

A S Kunin-Batson1,2, E G Shapiro3, K D Rudser4, C A Lavery5, K J Bjoraker6, S A Jones7, R F Wynn7, A Vellodi8, J Tolar2, P J Orchard2, J E Wraith7.   

Abstract

The long-term cognitive and functional outcomes of children with mucopolysaccharidosis type I (MPS-IH) post-hematopoietic cell transplant (HCT) are not well documented, and the role of genetic and treatment factors in these outcomes has yet to be defined. In this multi-site, international study, we (1) characterize the cognitive and functional status of 47 individuals (ages 2-25, mean of 10.6 years) with MPS-IH who are 1-24 years post HCT (mean = 9 years) and (2) examine contributions of genotype, transplant characteristics, and sociodemographic factors to cognitive ability, adaptive behavior, and quality of life. The overall cognitive ability of our sample was mildly impaired, more than two standard deviations below general population norms. Parent reported adaptive behaviors (i.e., communication, daily living, and motor skills) were similarly impaired with a relative strength in socialization. Quality of life, as reported by parents, fell more than two standard deviations below population norms for physical functioning; however, psychosocial quality of life (emotional well-being) approximated population norms. In linear regression analysis, adjusted for demographic and treatment factors, mutation severity was associated with lower cognitive ability (p = 0.005) and adaptive functioning (p = 0.004), but not parent ratings of children's quality of life. Older age at HCT was associated with poorer physical quality of life (p = 0.002); lower socioeconomic status (p = 0.028) and unrelated bone marrow HCT (p = 0.010) were associated with poorer psychosocial quality of life. Implications for screening and early intervention for children at risk for poorer cognitive and functional outcomes are described.

Entities:  

Year:  2016        PMID: 26825088      PMCID: PMC5059216          DOI: 10.1007/8904_2015_521

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  24 in total

Review 1.  Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?

Authors:  Satkiran S Grewal; Juliet N Barker; Stella M Davies; John E Wagner
Journal:  Blood       Date:  2003-01-09       Impact factor: 22.113

Review 2.  Health-related quality of life in survivors of BMT for paediatric malignancy: a systematic review of the literature.

Authors:  S-A Clarke; C Eiser; R Skinner
Journal:  Bone Marrow Transplant       Date:  2008-05-26       Impact factor: 5.483

Review 3.  The clinical outcome of Hurler syndrome after stem cell transplantation.

Authors:  Mieke Aldenhoven; Jaap Jan Boelens; Tom J de Koning
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

4.  Acute health-related quality of life in children undergoing stem cell transplant: II. Medical and demographic determinants.

Authors:  S Phipps; M Dunavant; S Lensing; S N Rai
Journal:  Bone Marrow Transplant       Date:  2002-03       Impact factor: 5.483

5.  Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study.

Authors:  Mieke Aldenhoven; Robert F Wynn; Paul J Orchard; Anne O'Meara; Paul Veys; Alain Fischer; Vassili Valayannopoulos; Benedicte Neven; Attilio Rovelli; Vinod K Prasad; Jakub Tolar; Heather Allewelt; Simon A Jones; Rossella Parini; Marleen Renard; Victoria Bordon; Nico M Wulffraat; Tom J de Koning; Elsa G Shapiro; Joanne Kurtzberg; Jaap Jan Boelens
Journal:  Blood       Date:  2015-01-26       Impact factor: 22.113

6.  Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome.

Authors:  Julie B Eisengart; Kyle D Rudser; Jakub Tolar; Paul J Orchard; Teresa Kivisto; Richard S Ziegler; Chester B Whitley; Elsa G Shapiro
Journal:  J Pediatr       Date:  2012-09-10       Impact factor: 4.406

7.  Long-term outcomes of adaptive functions for children with mucopolysaccharidosis I (Hurler syndrome) treated with hematopoietic stem cell transplantation.

Authors:  Kendra J Bjoraker; Kathleen Delaney; Charles Peters; William Krivit; Elsa G Shapiro
Journal:  J Dev Behav Pediatr       Date:  2006-08       Impact factor: 2.225

8.  The contribution of neurocognitive functioning to quality of life after childhood acute lymphoblastic leukemia.

Authors:  Alicia Kunin-Batson; Nina Kadan-Lottick; Joseph P Neglia
Journal:  Psychooncology       Date:  2014-02-04       Impact factor: 3.894

9.  Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources.

Authors:  G Souillet; N Guffon; I Maire; M Pujol; P Taylor; F Sevin; N Bleyzac; C Mulier; A Durin; K Kebaili; C Galambrun; Y Bertrand; R Froissart; C Dorche; L Gebuhrer; C Garin; J Berard; P Guibaud
Journal:  Bone Marrow Transplant       Date:  2003-06       Impact factor: 5.483

10.  Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years.

Authors:  Nathalie Guffon; Yves Bertrand; Isabelle Forest; Alain Fouilhoux; Roseline Froissart
Journal:  J Pediatr       Date:  2009-01-23       Impact factor: 4.406

View more
  17 in total

1.  Evaluation of non-reducing end pathologic glycosaminoglycan detection method for monitoring therapeutic response to enzyme replacement therapy in human mucopolysaccharidosis I.

Authors:  Moin U Vera; Steven Q Le; Alla Victoroff; Merry B Passage; Jillian R Brown; Brett E Crawford; Lynda E Polgreen; Agnes H Chen; Patricia I Dickson
Journal:  Mol Genet Metab       Date:  2019-09-11       Impact factor: 4.797

Review 2.  Lysosomal Leukodystrophies Lysosomal Storage Diseases Associated With White Matter Abnormalities.

Authors:  Gustavo H B Maegawa
Journal:  J Child Neurol       Date:  2019-02-13       Impact factor: 1.987

Review 3.  Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications.

Authors:  Alessandra Biffi
Journal:  Mol Ther       Date:  2017-04-04       Impact factor: 11.454

4.  Elevated cerebral spinal fluid biomarkers in children with mucopolysaccharidosis I-H.

Authors:  Gerald V Raymond; Marzia Pasquali; Lynda E Polgreen; Patricia I Dickson; Weston P Miller; Paul J Orchard; Troy C Lund
Journal:  Sci Rep       Date:  2016-12-02       Impact factor: 4.379

5.  Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial.

Authors:  Roberto Giugliani; Luciana Giugliani; Fabiano de Oliveira Poswar; Karina Carvalho Donis; Amauri Dalla Corte; Mathias Schmidt; Ruben J Boado; Igor Nestrasil; Carol Nguyen; Steven Chen; William M Pardridge
Journal:  Orphanet J Rare Dis       Date:  2018-07-05       Impact factor: 4.123

6.  Quality of life in mucopolysaccharidoses: construction of a specific measure using the focus group technique.

Authors:  M R Oliveira; I Schwartz; L S Costa; H Maia; M Ribeiro; L B Guerreiro; A Acosta; N S Rocha
Journal:  BMC Res Notes       Date:  2018-01-15

Review 7.  Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues.

Authors:  Christian J Hendriksz; Kenneth I Berger; Christina Lampe; Susanne G Kircher; Paul J Orchard; Rebecca Southall; Sarah Long; Stephen Sande; Jeffrey I Gold
Journal:  Orphanet J Rare Dis       Date:  2016-08-26       Impact factor: 4.123

8.  Beneath the floor: re-analysis of neurodevelopmental outcomes in untreated Hurler syndrome.

Authors:  Elsa G Shapiro; Chester B Whitley; Julie B Eisengart
Journal:  Orphanet J Rare Dis       Date:  2018-05-11       Impact factor: 4.123

Review 9.  Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology.

Authors:  Christiane S Hampe; Julie B Eisengart; Troy C Lund; Paul J Orchard; Monika Swietlicka; Jacob Wesley; R Scott McIvor
Journal:  Cells       Date:  2020-08-05       Impact factor: 6.600

Review 10.  Pain in Mucopolysaccharidoses: Analysis of the Problem and Possible Treatments.

Authors:  Sabrina Congedi; Marcello Orzalesi; Chiara Di Pede; Franca Benini
Journal:  Int J Mol Sci       Date:  2018-10-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.